Effect of the CYP3A inhibitors, diltiazem and ketoconazole, on ticagrelor pharmacokinetics in healthy volunteers

OBJECTIVES: Two open-label, two-period, crossover studies in healthy volunteers were designed to determine the pharmacokinetic interactions between ticagrelor, a P2Y(12) receptor antagonist, and a moderate (diltiazem) and a strong (ketoconazole) cytochrome P450 (CYP) 3A inhibitor. METHODS: Seventeen...

Descripción completa

Detalles Bibliográficos
Autores principales: Teng, Renli, Butler, Kathleen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Maney Publishing 2013
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937655/
https://www.ncbi.nlm.nih.gov/pubmed/27536435
http://dx.doi.org/10.3109/21556660.2013.785413

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937655/
https://www.ncbi.nlm.nih.gov/pubmed/27536435
http://dx.doi.org/10.3109/21556660.2013.785413

Ejemplares similares